Dogwood Therapeutics Inc., a development-stage biotechnology company, has announced the enrollment of the first 50 patients in its ongoing Phase 2b clinical trial for Halneuron®, a treatment for Chemotherapy-Induced Neuropathic Pain (CINP). The company remains on track to conduct an interim analysis of approximately 100 patients, with results anticipated in the fourth quarter of 2025. Halneuron® is being evaluated for its safety and efficacy against a placebo in cancer patients with neuropathy resulting from platinum or taxane-based chemotherapy regimens. The trial involves 8 once daily subcutaneous doses over 14 days, with a 28-day follow-up period. Primary endpoints include overall safety and changes in pain intensity, while secondary measures assess effects on sleep, fatigue, and overall health. Full results from the Phase 2b trial are expected in mid-2026.